Oncolytics Biotech Inc T.ONC

Multiple Myeloma In General and NCT03605719 Specifically

[pelaboost]

A poster elsewhere mentioned MM results, and I cannot find them.

I was prompted to look up the above noted MM trial. It added the CPI Opdivo - BMS. It is worth noting that this trial added the CPI to a combo that was already said to have been very promising. It is also worth noting that the Actual Completion Date was October 2022, as compared to the Anticipated date of May 2024. In my limited experience those dates are usually reveresed; that is to say actual date is after the anticipated date. This was a Phase 1 trial.

Another note of interest; it is possible but highly unlikely to receive Accelerated Approval off a Phase 1 trial. I am in no way suggesting that that factoid applies to the above.

Three Questions.
1. What MM trial was the other poster referring to?
2. If not the above trial, where are the results for it?
and most importantly
3. Is there an effort at Head Office to package and present all the goods ONC/Y has to offer?

[pelaboost]

Thought I would look a little deeper. News Release: BMS  -  Dec. 6. 2023. Tokyo The essence is that Abecma (BMS) becomes First CAR T approved for use in earlier lines of therapy for RRMM patients in Japan. BMS is one of the leaders in MM with a broad reach. They have been very quiet about the trial with ONC. Opdivo (BMS) got added to a pela combo that already had legs. Add to that

[inthno]

From November 16th 2017 the AN agreement. Japan is NOT included. Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN® Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan

[pelaboost]

@inthno. Thank you. I thought that was the case, and just now checked myself. I was looking at the presentation and MM has almost been purged with the exception of a small mention of BMS. I do not have a problem with the purge but find it a little curious. Anyway, I have been wondering for quite a while why we went after solid tumors with CAR T. I do now wonder if BMS would be interested in pela

[inthno]

IMO only generally and especially if it is IV administration which onc is then it is trying to target more than just the main tumour. Also pela has shown in previous studies where they were targeting a solid tumour and the liver mets disappeared completely in the patient. It used to be showcased in the investor presentions but that was some time ago although I do still have a lot of the old

[Noteable]

How many times have I posted that pelareorep is delivered by intravenous injection (IV)?  .. Obviously not enough for some.